IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: A phase I dose-escalation study

被引：0
|
作者：
Liu, Rujiao
Hu, Xichun
Song, Zhengbo
Zhang, Jian
Jin, Jianan
Gao, Shuiping
Sun, Yuping
Zhang, Yan
Gao, Shegan
Jia, Ruinuo
Jing, Deqiang
Xu, Yu
Wang, Zhenjiu
Lu, Qiying
Tian, Wenzhi
Cheng, Xiangdong
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[3] Shandong Prov Inst Canc Prevent & Treatment, Jinan, Peoples R China
[4] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[5] ImmuneOnco Biopharmaceut Shanghai Inc, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14506
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preliminary results of a phase I dose escalation study of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced tumors
    Cheng, Xiangdong
    Song, Zhengbo
    Zhang, Jian
    Jin, Jianan
    Gao, Shuiping
    Liu, Rujiao
    Sun, Yuping
    Zhang, Yan
    Gao, Shegan
    Jia, Ruinuo
    Jing, Deqiang
    Xu, Yu
    Zheng, Lina
    Zhao, Xiwen
    Li, Wei
    Lu, Qiying
    Tian, Wenzhi
    Hu, Xichun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Phase I study of anti-PD-L1 antibody MPDL3280A in patients with advanced solid tumors
    Murakami, Haruyasu
    Yamamoto, Noboru
    Kenmotsu, Hirotsugu
    Takahashi, Toshiaki
    Fujiwara, Yutaka
    Mizugaki, Hidenori
    Ishida, Yoshimasa
    Kawakami, Tomohisa
    ANNALS OF ONCOLOGY, 2015, 26 : 98 - 98
  • [3] Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
    Coward, Jermaine
    Mislang, Anna Rachelle Austria
    Frentzas, Sophia
    Lemech, Charlotte Rose
    Nagrial, Adnan
    Jin, Xiaoping
    Li, Baiyong
    Wang, Zhongmin Maxwell
    Kwek, Kon Yew
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
    Cao, Junning
    Ji, Dongmei
    Chen, Zhiyu
    Shen, Weina
    Wang, Jin
    Li, Baoyue
    Chi, Haidong
    Long, Amanda
    Gao, Ling
    Li, Jin
    ONCOLOGIST, 2017, 22 (06): : 638 - +
  • [5] Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
    Demetri, George D.
    Lo Russo, Patricia
    MacPherson, Lain R. J.
    Wang, Ding
    Morgan, Jeffrey A.
    Brunton, Valerie G.
    Paliwal, Prashni
    Agrawal, Shruti
    Voi, Maurizio
    Evan, T. R. Jeffry
    CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6232 - 6240
  • [6] Phase I study of KN035, a novel fusion Anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA
    Papadopoulos, K. P.
    Harb, W.
    Lu, N.
    Ma, X.
    He, Y.
    Yuan, L.
    Fu, M.
    Lin, Y.
    Xu, W.
    Wang, X.
    Wang, P.
    Xu, T.
    Dong, R.
    Gong, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 405 - 405
  • [7] IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study
    Wang, Shusen
    Zhang, Qingyuan
    Gao, Quanli
    Wu, Shikai
    Li, Enxiao
    Li, Zhi-hua
    Liu, Ziquan
    Zhao, Xiwen
    Gao, Siman
    Lu, Qiying
    Tian, Wenzhi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study
    Wang, Shusen
    Zheng, Qiufan
    Gao, Quanli
    Zhang, Qingyuan
    Wu, Shikai
    Li, Zhihua
    Li, Enxiao
    Lu, Qiying
    Gan, Frank
    Tian, Wenzhi
    CANCER RESEARCH, 2024, 84 (07)
  • [9] Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
    Haluska, Paul
    Menefee, Michael
    Plimack, Elizabeth R.
    Rosenberg, Jonathan
    Northfelt, Donald
    LaVallee, Theresa
    Shi, Li
    Yu, Xiang-Qing
    Burke, Patricia
    Huang, Jaiqi
    Viner, Jaye
    McDevitt, Jennifer
    LoRusso, Patricia
    CLINICAL CANCER RESEARCH, 2014, 20 (18) : 4747 - 4757
  • [10] A phase 1 study of IMC-001, novel anti-PD-L1 antibody, in patients with advanced solid tumors
    Keam, Bhumsuk
    Kim, Tae Min
    Oh, Do-Youn
    Ock, Chan-Young
    Kang, Won Ki
    Park, Yeon Hee
    Lee, Jeeyun
    Lee, Ji Hye
    Song, Yun Jeong
    Park, Young Suk
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
12345